Alumis Cash Flow Statement
NASDAQ: ALMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alumis free cash flow
In fiscal 2025, Alumis generated -$369.5 million of operating cash flow and spent $653,000 on capital expenditures. That left free cash flow of -$370.2 million, a free-cash-flow margin of -1539.2% of revenue. Alumis returned $17,000 to shareholders through share repurchases.
Summary generated from market data by MetaCap's automated system. Methodology
Alumis cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Net Income | -243.32M | -294.23M | -154.99M |
| Net Income growth (YoY) | — | — | — |
| Depreciation & Amortization | 3.50M | 3.15M | 1.28M |
| Stock-Based Compensation | 43.52M | 19.46M | 8.63M |
| Change in Working Capital | -1.97M | 5.64M | -982.00K |
| Operating Cash Flow | -369.52M | -255.08M | -129.97M |
| Capital Expenditures | -653.00K | -1.73M | -4.50M |
| Investing Cash Flow | 287.88M | -113.79M | 60.47M |
| Share Repurchases | -17.00K | -6.00K | -64.00K |
| Financing Cash Flow | 2.07M | 492.37M | 89.68M |
| Net Change in Cash | -79.58M | 123.50M | 20.18M |
| Free Cash Flow | -370.18M | -256.81M | -134.47M |
This table shows 3 annual periods of Alumis's cash flow statement, from FY 2025 back to FY 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ALMS's reporting calendar. What is a cash flow statement?